Arizona Kidney Disease & Hypertension Center competitors

Dr. Ellison has served as our President and Chief Executive Officer since April 2020 and as a Director on our Board since January 2020. Dr. Ellison’s broad experience and leadership positions include Chief Executive Officer of the privately held biotechnology company, Promedior, Inc. (acquired by Roche); President and Chief Executive Officer of Bond Biosciences, Inc., a biotech start-up developing a drug addressing the toxic impact of iron overload in the body; Executive Director of Torreya Advisors, LLC, a life sciences investment banking firm; Chairman and Chief Executive Officer of Assembly Biosciences, Inc. (formerly Ventrus Biosciences, Inc.); Executive Vice President of Paramount Biosciences LLC, a global drug development and healthcare investment firm; Vice President of Clinical Development of FibroGen, Inc., where he played a key role in the early phase development of roxadustat in anemia for chronic kidney disease (CKD) patients; Vice President of Medical Affairs and Chief Medical Officer of Sanofi-Synthelabo US, Inc.; and Vice President, Medical Affairs and Chief Medical Officer of Hoffman La Roche, Inc. in the United States. Dr. Ellison previously served as an Independent Board Director for several private and public companies, including Cougar Biotechnology Inc.; ProSanos Corporation; Cormedix Inc., a cardio-renal clinical stage company; and Mt. Cook, a urology-focused company. Dr. Ellison received a Master of Science degree from the London School of Tropical Medicine and Hygiene, and an M.D. from the University of British Columbia.

As the Chief Executive Officer of Florida Cancer Specialists (FCS), Nathan Walcker oversees implementation of the organization’s mission to provide world-class cancer care, close to home in community-based settings across the state of Florida. He leads the development of strategic initiatives that continue to drive FCS forward as a national cancer care leader. His top priorities as CEO are three-fold: 1) ensuring that patients battling cancer receive the highest quality clinical care with convenient access to innovative treatment options, 2) investing in early phase drug development, research and novel treatments, and 3) delivering a relentless focus on operational, clinical and financial excellence. Walcker joined FCS in 2019 as Chief Financial Officer, bringing more than a decade of diverse healthcare, physician services and corporate finance expertise with him to Fort Myers. He was appointed CEO in 2020. Previously, he served as a key member of Bank of America Merrill Lynch’s Global Healthcare Investment Banking group in New York, advising the firm’s public and emerging growth health care clients and leading private equity firms. Walcker began his career on Wall Street on the Merrill Lynch trading floor in New York and went on to assume increasing responsibilities as an Investment Banker and strategic advisor to corporations, entrepreneurs and public company boards. Walcker earned an MBA from Columbia Business School and a bachelor’s degree in Economics from Columbia University. Since joining FCS, Walcker has made significant contributions across finance and accounting operations, business planning and strategy, and fiscal compliance policy and practices. He was instrumental in guiding cost containment efforts that have enabled the ongoing delivery of patient care with minimal disruption throughout global COVID-19 pandemic. Making a difference and driving change are critically important to Walcker, who is inspired daily by the dedication and commitment of his many FCS teammates. “FCS is a really special organization,” he says. “Our shared commitment to patient care, quality, innovation and teamwork drives everything we do, and every choice we make as an organization.” Deeply committed to community service, Walcker serves on several community boards including American Cancer Society’s CEOs Against Cancer. He previously served as a board member of Lime Connect, a nonprofit that connects high potential students and professionals with disabilities with professional development opportunities.

Alex Liang is a President and Chief Executive Officer at Dallas Nephrology Associates. He has worked as Vice president at Dallas Nephrology Associates. Alex attended Baylor College of Medicine between 1997 and 2000, Northwestern University Feinberg School of Medicine between 2000 and 2002, and UT Southwestern Medical Center between 1993 and 1997.

Karl Bolton is a Chief Executive Officer at Umpqua Community Health Center.

Paul Lynch is a Co-Founder and Chief Executive Officer at Arizona Pain Specialists and is based in Scottsdale, Arizona.

The ENT Institute is a Center of Excellence for Ear, Nose and Throat Disorders. At DRG Media we have proven advertising strategies to grow businesses using an effective marketing strategy to encompass Video, Live Stream, Social Media and Traditional Media.